129 related articles for article (PubMed ID: 2405043)
1. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
[TBL] [Abstract][Full Text] [Related]
2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral physostigmine in Alzheimer's disease.
Stern Y; Sano M; Mayeux R
Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
[TBL] [Abstract][Full Text] [Related]
4. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
Schwartz AS; Kohlstaedt EV
Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
[TBL] [Abstract][Full Text] [Related]
5. The effect of long-term physostigmine administration in Alzheimer's disease.
Harrell LE; Callaway R; Morere D; Falgout J
Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
[TBL] [Abstract][Full Text] [Related]
6. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
[TBL] [Abstract][Full Text] [Related]
7. Long-term administration of oral physostigmine in Alzheimer's disease.
Stern Y; Sano M; Mayeux R
Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
[TBL] [Abstract][Full Text] [Related]
8. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
Gustafson L
Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
[TBL] [Abstract][Full Text] [Related]
9. Effects of physostigmine and lecithin on memory in Alzheimer disease.
Peters BH; Levin HS
Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
[TBL] [Abstract][Full Text] [Related]
10. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Wettstein A
Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R
Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658
[TBL] [Abstract][Full Text] [Related]
12. Oral physostigmine treatment of patients with Alzheimer's disease.
Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
[TBL] [Abstract][Full Text] [Related]
13. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
[TBL] [Abstract][Full Text] [Related]
14. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
[TBL] [Abstract][Full Text] [Related]
15. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.
Muramoto O; Sugishita M; Sugita H; Toyokura Y
Arch Neurol; 1979 Aug; 36(8):501-3. PubMed ID: 508162
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
Davis KL; Mohs RC
Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
[TBL] [Abstract][Full Text] [Related]
18. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
Jenike MA; Albert M; Baer L; Gunther J
J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
[TBL] [Abstract][Full Text] [Related]
19. Cortisol responses to cholinergic drugs in Alzheimer's disease.
Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
Beller SA; Overall JE; Swann AC
Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
